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ABSTRACT   
The mechanisms of efficacy for fecal microbiota transplantation (FMT) in treating recurrent 
Clostridioides difficile infection (rCDI) remain poorly defined, with restored gut microbiota-bile 
acid interactions representing one possible explanation.  Furthermore, the potential implications 
for host physiology of these FMT-related changes in gut bile acid metabolism are also not well 
explored.  In this study, we investigated the impact of FMT for rCDI upon signalling through the 
farnesoid X receptor (FXR)-fibroblast growth factor (FGF) pathway.  Herein, we identify that in 
addition to restoration of gut microbiota and bile acid profiles, FMT for rCDI is accompanied by 
a significant, sustained increase in circulating levels of FGF19 and reduction in FGF21. These 
FGF changes were associated with weight gain post-FMT, to a level not exceeding the pre-rCDI 
baseline. Collectively, these data support the hypothesis that the restoration of gut microbial 
communities by FMT for rCDI is associated with an upregulated FXR-FGF pathway, and highlight 
the potential systemic effect of FMT.  
 
Introduction 
Fecal microbiota transplantation (FMT) is a highly effective therapy against recurrent 
Clostridioides difficile infection (rCDI). However, the mechanisms by which FMT exerts its 
efficacy in rCDI remain unclear. In recent years, restoration of pre-morbid gut bile acid metabolism 
has become one of the better known potential mechanisms supported by both human and animal 
studies. Secondary bile acids inhibit C. difficile vegetative growth, while certain primary bile acids 
(and particularly taurocholic acid) promote germination.1 It has been demonstrated that secondary 
bile acid concentrations are much reduced while primary bile acid levels are elevated in rCDI 
patients compared to healthy controls, potentially perpetuating C. difficile proliferation.2 
Following FMT, which restores the diversity and composition of the intestinal microbiota, bile 
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acid homeostasis is re-established.2 Furthermore, there is also evidence that the loss of microbiota-
derived bile-metabolising enzymes may contribute to the pathogenesis of CDI both in mice and in 
humans.3–5 
 
   Bile acid metabolism is not only regulated by commensal bacteria, but also through farnesoid X 
receptors (FXR), which are abundantly expressed in the liver and ileum.6  In humans, the most 
potent endogenous ligand for FXR is the primary bile acid chenodeoxycholic acid (CDCA); the 
secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA) are moderate FXR 
agonists, whilst the primary bile acid cholic acid (CA) also has modest agonist activity.20  Upon 
ileal FXR activation, fibroblast growth factor (FGF)19 is secreted into the portal circulation, where 
it binds to the FGFR4/Klotho receptor complex on hepatocytes. This interaction acts as both a 
negative feedback control on hepatic bile acid synthesis through inhibition, and also as a modulator 
of key metabolic pathways involved in glucose, lipid, and energy metabolism.7 Although both 
FGF19 and FGF21 are involved in regulating multiple metabolic processes, they have an inverse 
relationship that collectively maintains metabolic homeostasis, since FGF19 is produced during 
feeding while FGF21 is secreted during fasting.8 Perturbation of FXR signalling and altered FGF 
levels have been found in a number of disease states, including type 2 diabetes, metabolic 
syndrome and Crohn’s disease.9,10  Furthermore, surgically-induced weight loss is associated with 
an increase in FGF19 and a decrease in FGF21 levels.9 
 
   There is growing evidence from murine studies that altered interaction between the gut 
microbiota and bile acids may directly affect FXR signalling. Germ-free and antibiotic-treated 
mice have markedly reduced ileal Fgf15 gene expression (murine orthologue of human FGF19).11 
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The resultant accumulation of tauro--muricholic acid (an FXR antagonist) is thought to be the 
link between alterations of the gut microbiota and FXR signalling in mice. However, given that 
this bile acid is only present at very modest levels in humans, coupled with the differences in FGF 
orthologues and microbiota between humans and mice, extrapolating these data to humans is 
problematic. Presently, there are no human studies to our knowledge examining the impact of 
antibiotic-induced dysbiosis on FXR signalling. Given the apparent key contribution of the 
microbiota-bile acid axis to CDI pathogenesis, we investigated the association between changes in 
bile acid composition and FGF19 and 21 following FMT for the treatment of rCDI in humans. To 
do this, we analysed samples collected from a recent randomised trial of capsulized vs 
colonoscopic FMT for the treatment of rCDI.12 We undertook metagenomic, metabonomic and 
proteomic analyses for these samples, and correlated with weight changes following rCDI 
eradication. 
 
Results 
a) Stool metagenome analysis 
We have previously described that successful FMT for rCDI is associated with both marked 
increases in stool microbial diversity and altered microbial community composition to resemble 
that of healthy donors, maintained up to at least 12 weeks post-FMT.12 Further analysis here 
demonstrated that successful FMT was particularly associated with enrichment of a number of 
bacterial genera including Bacteroides, Faecalibacterium, Ruminococcus, Blautia and 
Eubacterium (all of which contain members with bile acid-metabolising function) and loss of 
Klebsiella, Escherichia and Veillonella (which generally lack these functions) (Supplementary 
Figure 1).20  
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b) Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) stool bile acid 
profiling 
Successful FMT was also associated with significantly decreased stool levels of the primary bile 
acids CDCA and CA, and significantly increased levels of the secondary bile acids DCA and LCA 
(Figure 1).  In all cases, these changes were observed at four weeks post-FMT and were 
maintained at 12 weeks post-therapy. 
 
c) Proteomic analysis 
Of 73 compared proteomic markers (Supplementary Table 1), the differences were statistically 
significant for only two: FGF19 and FGF21 (Figure 2). FGF19 had significantly higher 
Normalized Protein eXpression (NPX) values at weeks 4 and 12 compared with screening, while 
FGF21 had significantly lower NPX values at weeks 4 and 12 compared with screening. There 
was no significant difference in the levels of FGF19 and FGF21 between the groups receiving 
FMT by either capsules or colonoscopy (data not shown). 
 
d) Differences in weight before and after FMT 
Following successful FMT, there was a statistically significant increase in mean BMI at 12 weeks 
following FMT compared to screening, but this did not exceed pre-rCDI baseline (mean BMI 
difference [95%CI], 0.5 [0.2, 0.8]; p = 0.003, Table 1. 
 
Discussion 
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While it has already been observed that FMT in humans with rCDI restores gut microbiota and 
bile acid composition, we demonstrate for the first time that this procedure is also associated with 
activation of ileal FXR signalling, manifested by increased FGF19 and reduced FGF21 expression. 
CDCA is the most potent endogenous ligand for FXR, although the secondary bile acids DCA and 
LCA are also moderate FXR agonists.  Our data suggest that the reduced level of a potent FXR 
agonist (CDCA) is offset by increased levels of two moderate FXR agonists (DCA and LCA),21 
with a net upregulation of the ileal FXR-FGF pathway following successful FMT. Some phases of 
this bile acid transformation process (e.g. 7- dehydroxylation) occur within the colon, implying 
that for secondary bile acids to affect ileal FXR signaling, they must be reabsorbed in the colon 
and re-secreted in bile into the small intestine.22 Although metabolism of bile acids in the gut is a 
bacterially-driven process,20 further studies are needed to examine the specific contribution of 
different bacteria to this process.  
 
   In addition to its well-defined roles in the regulation of metabolism and bile acid production, 
there is also evidence in how FXR signalling plays a role in other systemic processes relevant to 
CDI.  For example, FXR activation has been shown to inhibit bacterial overgrowth and block 
mucosal injury in mouse ileum,23 and is associated with reduced expression of key cytokines 
(including TNF- and IL-1) that regulate the host innate immune response.24  Moreover, the 
inflammatory response or C. difficile itself could reciprocally inhibit activation of FXR and its 
target FGF genes, and this therefore merits further study. 
 
   Although our data are consistent with previous studies in observing restoration of the gut 
microbiota and bile acid composition post-FMT for rCDI, there is no direct demonstration that this 
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pathway is a key mechanism underpinning the efficacy of FMT for rCDI.  In addition, it is not 
clear if the observed weight gain following FMT is directly mediated through changes in 
FGF19/21 levels. Future mechanistic studies involving mouse models of CDI would be required 
to determine causality, and such studies should consider including analysis of the effect of FMT 
upon FXR signalling.  Should these experiments validate our preliminary findings, the bile acid-
FXR axis may become a novel therapeutic target for the treatment of rCDI.  There are already 
some data that would appear to support this strategy; specifically, the potent FXR agonist 
obeticholic acid (INT-747) has been shown to display anti-C. difficile potential in murine models 
of CDI.25 However, the benefits and risks of synthetic FXR ligands require further evaluation. 
 
   In conclusion, our data suggest that FMT is associated with upregulation of the bile acid-FXR-
FGF signalling pathway, and this may possibly explain the rapid improvement in energy and well-
being many patients experience following FMT. Although these findings are intriguing, we 
acknowledge several limitations, including small sample size, short follow-up period, the 
observational nature of the data, lack of mucosal inflammatory protein expression data, and non-
consideration of diet or host genetics.  Insights gleaned from better understanding of FMT 
mechanisms of action using a multi-omics approach could enable development of tailored 
therapies that target key signaling pathways or specific constituents of those pathways that may 
regulate host defence to circumvent various concerns surrounding FMT. 
 
Materials and Methods 
a) Patient clinical data, sample collection and storage 
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Participants (n=116) in the capsule vs colonoscopy-delivered FMT trial were included this pilot 
study.12 Blood and stool samples were collected, and body mass indices (BMI) documented at 
screening and subsequent follow-up visits at weeks 4 and 12 after FMT. Of the 64 patients 
recruited from Edmonton, 43 had complete sets of archived blood samples and were subjected to 
proteomic analyses using the Olink inflammation panel. Of these 43 patients, 23 were chosen at 
random to have their stool samples undergo microbial composition analysis by shotgun 
metagenomics sequencing. From these 23 patients, 17 randomly-selected patients had stool bile 
acid profiling by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). 
Patient baseline characteristics are shown in Table 2. The metagenomic, metabonomic, and 
proteomic results were correlated with weight changes following rCDI eradication. This study was 
approved by the research ethics board of the University of Alberta (Pro49006). 
 
b) Stool metagenomics 
Whole-genome shotgun sequencing was performed as previously described.12 More specifically, 
taxonomic classification of reads from each library was conducted with Kraken.13 The database 
used consisted of all bacteria, archaea, viruses, fungi, and protozoa full-length genomes from 
NCBI RefSeq, the human genome assembly GRCh38, and reference bacterial assemblies from the 
Human Microbiome Project.14 Read assignments were filtered with Kraken-filter using a threshold 
of 10%. 
 
c) UPLC-MS profiling of fecal bile acids 
Sample preparation was performed using protocols as previously-described.15  Bile acid analysis 
of faecal extracts was performed using ACQUITY UPLC (Waters Ltd, Elstree, UK) coupled to a 
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Xevo G2 Q-ToF mass spectrometer equipped with an electrospray ionization source operating in 
negative ion mode (ESI-), using the method described by Sarafian and colleagues.16 Waters raw 
data files were converted to NetCDF format and data extracted using the XCMS (v1.50) package 
in R (v3.1.1) software. Probabilistic quotient normalisation17 was used to correct for dilution 
effects and chromatographic features with coefficient of variation higher than 30% in the QC 
samples were excluded from further analysis. The relative intensities of the features were corrected 
to the dry weight of the faecal samples. 
 
d) Proteomics 
The relative levels of serum inflammatory proteins were analyzed with Olink® Inflammation I 
panel (Olink Proteomics AB, Uppsala, Sweden) using Proximity Extension Assay (PEA) 
according to the manufacturer’s instructions.18,19  A list of the 92 inflammation-related markers is 
listed in Supplementary Table 2. In brief, serum samples (1µL) were incubated with 92 
oligonucleotide labelled antibody probe pairs that bind to their respective target in the sample. A 
PCR reporter sequence was formed by a proximity dependent DNA polymerization event and was 
subsequently detected and amplified using a microfluidic real-time PCR instrument (Biomark HD, 
Fluidigm). Data was then quality controlled and normalized using an internal extension control 
and an inter-plate control, to adjust for intra- and inter-run variation. The final assay read-out is 
presented in Normalized Protein eXpression (NPX) values, which is an arbitrary unit on a log2-
scale where a high value corresponds to a higher protein expression. All assay validation data 
(detection limits, intra- and inter-assay precision data, etc) are available on the manufacturer's 
website (http://www.olink.com). Samples failing technical quality controls or that fell below lower 
limits of detection were excluded from analyses.  
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e) Statistical Analysis 
Full methodology for statistical analysis is provided in the Supplementary Material.  
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Figure 1. Effect of FMT for rCDI upon bile acid profiles. A significant decrease in 
chenodeoxycholic acid (A) and cholic acid (B) is seen between screening and 4 weeks, and 
maintained up to 12 weeks post-FMT. A significant increase in lithocholic acid (C) and 
deoxycholic acid (D) is observed between screening and 4 weeks, and maintained up to 12 weeks 
post-FMT. X-axis depicts time, and y-axis depicts relative intensity of each bile acid. Pre-FMT = 
screening; week 4 = 4 weeks after fecal microbiota transplantation (FMT); week 12 = 12 weeks 
post-FMT.  
 
Figure 2. Normalized Protein eXpression (NPX) values for serum fibroblast growth factor 
(FGF)19 (A) and FGF21 (B) over time. There is a statistically significant increase in FGF19 
level 4 and 12 weeks after FMT compared to screening, while a statistically significant decrease 
in FGF21 level is observed 4 and 12 weeks following FMT. X-axis depicts time, and y-axis depicts 
relative quantification of respective FGF. Circles represent mean; error bars represent standard 
deviation.  
 
 
Table 1. Comparison of the mean body mass index (BMI) over time. At week 4, the mean BMI was not 
significantly different from the mean BMI prior to FMT. At week 12, patients had significantly higher BMI 
relative to pre-FMT, but did not exceed pre-rCDI baseline.  
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  Mean BMI Difference (95% CI) p value 
Week 4 - Pre-FMT 0.0 (-0.3, 0.3) 0.84 
Week 12 - Pre-FMT 0.5 (0.2, 0.8) 0.003 
Week 12 - Week 4 0.4 (0.1, 0.8) 0.006 
 
 
Table 2. Patient baseline characteristics 
Variable Blood proteomics analysis 
(n=43) 
Stool bile acid analysis 
(n=17) 
Age, mean (SD), y 58.8 (19.2) 58.1 (17.1) 
Female, No. (%) 27 (62.8%) 13 (76%) 
Charlson Comorbidity Index score, median 
(Q1-Q3) 
3 (1-5) 3 (1-4) 
Immunosuppressed patients, No. (%) 5 (11.6%) 0 
BMI, mean (SD) 25.9 (5.9) 27.5 (6.0) 
PPI use prior to FMT, No. (%) 5 (11.6%) 2 (11.7%) 
Hemoglobin, median (Q1-Q3), g/dL 13.8 (13.0-14.4) 13.9 (13.1-14.5) 
White blood cell count, median (Q1-Q3), /uL 7100 (5850-8500) 6750 (5620-8130) 
Albumin, median (Q1-Q3), g/dL 4.0 (3.8-4.3) 4.0 (3.9-4.3) 
C-reactive protein, median (Q1-Q3), mg/dL 0.29 (0.085-0.10) 0.30 (0.075-0.89) 
Creatinine, median (Q1-Q3), mg/dL 0.75 (0.66-0.87) 0.74 (0.66-0.94) 
Capsule delivered FMT, No. (%) 25 (58.1%) 11 (64.7%) 
Abbreviations: BMI, body mass index; FMT, fecal microbiota transplantation; PPI, proton pump inhibitor; 
Q1, first quartile; Q3, third quartile.  
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Supplementary Material
Effective fecal microbiota transplantation for recurrent Clostridium difficile infection in 
humans is associated with increased signalling in bile acid-farnesoid X receptor-
fibroblast growth factor pathway 
Supplementary material: 
1. Materials and methods  
1.1.Sample collection and storage 
   Whole blood samples were collected and initially stored at room temperature for up to 2 
hours before being centrifuged for ten minutes at 1.5 RCF (relative centrifugal force). The 
serum samples were subsequently transferred to new collection tubes and stored at -80⁰ C 
before proteomics profiling. Stool samples were collected by patients at home and stored at 
40C for up to 8 hours; these samples were aliquoted and stored at -80⁰ C before further 
analyses.  
 
1.2.Statistical Analysis 
   Changes in BMI over time were analyzed using the mixed effects model with SAS version 
9.4 (SAS Institute). 
   For metagenomic data analysis, genus-level extended error bar plots were generated using 
the Statistical Analysis of Metagenomic Profiles (STAMP) software package using White’s 
non-parametric t-test with Benjamini-Hochberg FDR correction.1   
    Of the 92 proteins measured (Supplementary Table 2), 19 appeared to be below the 
detection limit for > 25% of the samples and thus were excluded from the analysis. For each 
group undergoing proteomic analysis, mean values with standard deviation and 95% group 
confidence intervals of protein expression of 73/92 investigated inflammation-associated 
markers were determined.  Systematic changes in protein levels between time points (screening 
vs 4 weeks vs 12 weeks post FMT) were examined using a general linear model repeated-
Supplementary Material
measures ANOVA. The threshold for statistical significance was set at an alpha = 0.01. Wilk’s 
Lambda test for multivariate comparison of time points [indicates whether or not the within-
subject means of more than two groups (time points) are statistically significant and where the 
null hypothesis is rejected if the Wilk’s lamda is small or close to zero] and Greenhouse-Geisser 
Epilson tests for Sphericity were performed. The Bonferroni method was used to adjust for 
multiple comparisons between time points and adjusted p values have been presented in 
Supplementary Table 1. For residual analysis, Shapiro-Wilk’s test for residual normality and 
visual inspection of residual plots plotted against fitted values for heteroscedasticity were also 
performed. Statistical analyses were conducted using IBM SPSS statistic package version 22 
(IBM, Armonk, New York, USA).  
   For bile acid data, pre-FMT and post-FMT samples were compared Wilcoxon Rank-Sum test 
where p values less than 0.05 were considered as statistically significant. Statistical analyses 
were carried out using GraphPad Prism 7 software (GraphPad Software, USA). 
 
Supplementary Figure 1:  Effect of FMT for rCDI upon genus-level gut microbial 
profiles.  Extended error bar plots, with genera changing significantly measured by White’s 
non-parametric test with Benjamini-Hochberg correction, using threshold between mean 
proportions of >1%. (A) pre-FMT vs 4 weeks post-FMT; (B) pre-FMT vs 12 weeks post-FMT.  
 
Supplementary Table 1: Effect of FMT for rCDI upon Normalised Protein Expression 
Units (NPX) values with Bonferroni correction (alpha = 0.01). Pre-FMT vs 4 weeks post-
FMT; Pre-FMT vs 12 weeks post FMT; week 4 vs week 12 post-FMT by repeated-measures 
ANOVA.  
 
Supplementary Table 2. List of 92 proteins measured by high-throughput, multiplex 
immunoassays Inflammation I panel by Olink® (Olink Proteomics AB, Uppsala, Sweden) 
 
Supplementary References: 
1. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of 
taxonomic and functional profiles. Bioinformatics (Oxford, England) 2014; 30:3123-4. 
 
Supplementary Table 1. Effect of FMT for rCDI upon Normalised Protein Expression Units (NPX) 
values with Bonferroni correction (alpha = 0.01). Pre-FMT vs 4 weeks post-FMT; Pre-FMT vs 12 
weeks post FMT; week 4 vs week 12 post-FMT by repeated-measures ANOVA.  
Protein 
 Time Point 
Repeated 
Measure 
ANOVA 
Multiple Comparision p-values (Bonferroni 
Correction, α=0.01) 
Pre-FMT Week4 week12 
Wilk's 
Lambda 
test (p-
values) 
Pre FMT - 
Week4 
Pre FMT - 
Week12 
Week4 - 
Week12 
IL8 10.90(1.94) 10.58(1.63) 10.42(2.16) 0.729 0.753 0.940 1.000 
VEGFA 10.65(0.64) 10.58(0.65) 10.65(0.69) 0.847 1.000 1.000 1.000 
MCP-3 4.87(1.7) 4.53(1.5) 4.29(1.76) 0.311 0.438 0.594 1.000 
GDNF 1.02(0.56) 0.9(0.5) 0.91(0.51) 0.311 0.465 0.574 0.465 
CDCP1 3.6(1.03) 3.56(0.99) 3.54(1.03) 0.962 1.000 1.000 1.000 
CD244 6.38(0.32) 6.33(0.36) 6.31(0.38) 0.728 1.000 1.000 1.000 
IL7 3.92(0.95) 3.81(0.97) 3.93(0.99) 0.940 1.000 1.000 1.000 
OPG 10.85(0.51) 10.73(0.54) 10.8(0.56) 0.657 1.000 1.000 1.000 
LAP 
TGF-
beta-1 
8.33(0.3) 8.3(0.33) 8.29(0.31) 
0.736 1.000 1.000 1.000 
uPA 10.41(0.41) 10.4(0.46) 10.4(0.45) 0.899 1.000 1.000 1.000 
IL6 4.39(1.77) 4.02(1.19) 4.18(1.83) 0.475 0.655 1.000 1.000 
IL-17C 1.19(0.79) 1.11(1.03) 1.12(0.86) 0.622 1.000 0.984 1.000 
MCP-1 10.8(0.62) 10.75(0.73) 10.65(0.52) 0.607 1.000 0.988 1.000 
CXCL11 8.97(0.69) 8.99(0.93) 8.71(0.81) 0.026 1.000 0.045 0.311 
AXIN1 4.88(0.47) 4.86(0.46) 4.82(0.7) 0.859 1.000 1.000 1.000 
TRAIL 8.23(0.39) 8.23(0.35) 8.23(0.31) 0.847 1.000 1.000 1.000 
CXCL9 8.03(1.24) 7.92(1.53) 7.77(1.32) 0.625 1.000 1.000 1.000 
CST5 6.3(0.87) 6.35(0.78) 6.44(1.01) 0.512 1.000 0.730 1.000 
OSM 5.86(0.97) 5.98(0.91) 6.09(1.04) 0.475 1.000 0.685 1.000 
CXCL1 8.25(0.91) 8.03(0.63) 8(0.86) 0.232 0.346 0.287 1.000 
CCL4 7.85(0.75) 7.77(0.74) 7.76(0.83) 0.56 1.000 0.837 1.000 
CD6 5.05(0.6) 5.14(0.72) 5.25(0.58) 0.25 0.988 0.316 1.000 
SCF 9.87(0.43) 9.75(0.44) 9.82(0.34) 0.341 0.532 0.072 0.055 
IL18 8.24(0.62) 8.21(0.53) 8.07(0.56) 0.031 1.000 0.096 0.037 
SLAMF1 1.94(0.67) 1.96(0.57) 1.9(0.66) 0.905 1.000 1.000 1.000 
TGF-
alpha 
3.49(0.62) 3.69(0.56) 3.73(0.58) 0.121 0.143 0.189 1.000 
MCP-4 4.69(0.53) 4.53(0.56) 4.58(0.58) 0.457 0.696 1.000 1.000 
CCL11 8.29(0.53) 8.31(0.51) 8.43(0.49) 0.414 1.000 0.545 1.000 
TNFSF14 7.17(0.63) 7.21(0.6) 7.18(0.75) 0.825 1.000 1.000 1.000 
Supplementary Material
FGF-23 1.86(1.67) 1.73(1.56) 1.85(1.65) 0.437 1.000 1.000 0.833 
IL-10RA 1.46(0.88) 1.44(0.87) 1.25(0.37) 0.881 1.000 1.000 1.000 
FGF-5 1.31(0.32) 1.31(0.35) 1.31(0.39) 0.644 1.000 1.000 1.000 
MMP-1 14.3(0.78) 14.34(0.76) 14.22(0.9) 0.66 1.000 1.000 1.000 
LIF-R 3.06(0.35) 3.03(0.39) 3.04(0.38) 0.908 1.000 1.000 1.000 
FGF-21 6.42(1.67) 5.53(1.79) 5.63(1.43) <0.0001 <0.0001 <0.0001 1.000 
CCL19 9(1.11) 8.97(1.09) 8.82(1.17) 0.621 1.000 1.000 1.000 
IL-15RA 0.51(0.36) 0.45(0.36) 0.46(0.33) 0.690 1.000 1.000 1.000 
IL-10RB 7(0.45) 6.93(0.43) 6.99(0.48) 0.949 1.000 1.000 1.000 
IL-18R1 7.11(0.54) 7.14(0.6) 7.15(0.57) 0.974 1.000 1.000 1.000 
PD-L1 4.11(0.66) 4.04(0.65) 3.94(0.71) 0.241 1.000 0.363 0.488 
Beta-
NGF 
1.78(0.31) 1.7(0.34) 1.64(0.37) 0.114 0.521 0.109 0.657 
CXCL5 11.22(1.36) 11.15(1.15) 10.92(1.19) 0.326 1.000 0.475 0.737 
TRANCE 4.25(0.66) 4.11(0.61) 3.93(0.55) 0.025 0.605 0.019 0.583 
HGF 8.94(0.56) 8.89(0.51) 8.99(0.55) 0.777 1.000 1.000 1.000 
IL-12B 4.72(0.73) 4.47(0.92) 4.47(0.93) 0.025 0.071 0.063 1.000 
MMP-10 6.2(0.82) 6.12(0.91) 6.1(0.74) 0.471 1.000 0.901 0.920 
IL10 3.18(0.85) 3.24(0.85) 3.17(0.84) 0.634 1.000 1.000 1.000 
CCL23 10.03(0.53) 9.81(0.67) 9.8(0.64) 0.106 0.226 0.181 0.226 
CD5 5.4(0.49) 5.37(0.62) 5.48(0.5) 0.58 1.000 0.900 1.000 
CCL3 5.93(1.13) 5.76(0.88) 5.8(1.25) 0.604 1.000 1.000 1.000 
Flt3L 9.02(0.6) 9.07(0.57) 9(0.63) 0.226 0.324 1.000 0.925 
CXCL6 8.28(0.86) 8.19(0.62) 7.9(0.83) 0.03 0.845 0.038 0.047 
CXCL10 8.49(0.77) 8.5(1.13) 8.26(1.06) 0.239 1.000 0.422 0.468 
4E-BP1 9.23(1.05) 9.21(1.25) 9.46(1.23) 0.382 1.000 0.488 1.000 
SIRT2 4.84(0.55) 4.82(0.94) 4.91(0.92) 0.774 1.000 1.000 1.000 
CCL28 2.05(0.62) 1.94(0.53) 1.94(0.57) 0.648 1.000 1.000 1.000 
DNER 8.16(0.35) 8.17(0.29) 8.13(0.32) 0.582 0.902 1.000 1.000 
EN-
RAGE 
5.42(1.15) 5.52(1.02) 5.35(1.02) 0.571 0.958 1.000 1.000 
CD40 11.28(0.43) 11.18(0.49) 11.24(0.48) 0.505 0.818 1.000 1.000 
FGF-19 8.07(1.38) 8.82(1.17) 8.95(1.12) <0.0001 <0.0001 0.001 1.000 
MCP-2 8.42(0.63) 8.48(0.81) 8.37(0.72) 0.648 1.000 1.000 1.000 
CASP-8 4.4(0.62) 4.24(0.57) 4.32(0.57) 0.512 0.748 1.000 1.000 
CCL25 6.28(0.72) 6.3(0.85) 6.46(0.72) 0.294 1.000 0.384 1.000 
CX3CL1 5.8(0.61) 5.69(0.64) 5.64(0.73) 0.731 1.000 1.000 1.000 
TNFRSF9 6.88(0.9) 6.56(0.93) 6.7(0.99) 0.049 0.042 0.387 0.042 
NT-3 1.14(0.57) 1.14(0.64) 1.07(0.75) 0.947 1.000 1.000 1.000 
TWEAK 9.95(0.43) 9.88(0.4) 9.83(0.4) 0.738 1.000 1.000 1.000 
STAMPB 5.42(0.52) 5.41(0.79) 5.51(0.8) 0.576 1.000 0.880 1.000 
CCL20 4.42(1.19) 4.47(1.41) 4.41(0.94) 0.69 1.000 1.000 1.000 
ST1A1 6.11(0.6) 6.03(0.56) 5.85(0.63) 0.063 1.000 0.092 0.338 
ADA 4.42(0.52) 4.39(0.61) 4.29(0.46) 0.516 1.000 0.742 1.000 
TNFB 3.94(0.49) 3.93(0.53) 3.9(0.6) 0.73 1.000 1.000 1.000 
CSF-1 8.29(0.29) 8.27(0.31) 8.27(0.32) 0.757 1.000 1.000 1.000 
        
 
 
Supplementary Table 2. List of 92 proteins measured by high-throughput, multiplex immunoassays 
Inflammation I panel by Olink® (Olink Proteomics AB, Uppsala, Sweden) 
Target Abbreviated form 
Adenosine Deaminase ADA 
Artemin ARTN 
Axin-1 AXIN1 
Beta-nerve growth factor Beta-NGF 
Brain-derived neurotrophic factor BDNF 
Caspase 8 CASP-8 
C-C motif chemokine 4 CCL4 
C-C motif chemokine 19 CCL19 
C-C motif chemokine 20 CCL20 
C-C motif chemokine 23 CCL23 
C-C motif chemokine 25 CCL25 
C-C motif chemokine 28 CCL28 
CD40L receptor CD40 
CUB domain-containing protein 1 CDCP1 
C-X-C motif chemokine 1 CXCL1 
C-X-C motif chemokine 5 CXCL5 
C-X-C motif chemokine 6 CXCL6 
C-X-C motif chemokine 9 CXCL9 
C-X-C motif chemokine 10 CXCL10 
C-X-C motif chemokine 11 CXCL11 
Cystatin D CST5 
Delta and Notch-like epidermal growth factor-related receptor DNER 
Eotaxin-1 CCL11 
Eukaryotic translation initiation factor 4E-binding protein 1 4E-BP1 
Fibroblast growth factor 5 FGF-5 
Fibroblast growth factor 19 FGF-19 
Fibroblast growth factor 21 FGF-21 
Fibroblast growth factor 23 FGF-23 
Fms-related tyrosine kinase 3 ligand Flt3L 
Fractalkine CXC3CL1 
Glial cell line-derived neurotrophic factor hGDNF 
Hepatocyte growth factor HGF 
Intereron gamma IFN-gamma 
Interleukin-1 alpha IL-1 alpha 
Interleukin-2 IL-2 
Interleukin-2 receptor subunit beta IL-2RB 
Interleukin-4 IL-4 
Interleukin-5 IL-5 
Interleukin-6 IL-6 
Interleukin-7 IL-7 
Interleukin-8 IL-8 
Interleukin-10 IL-10 
Interleukin-10 receptor subunit alpha IL-10RA 
Interleukin-10 receptor subunit beta IL-10RB 
Interleukin-12 subunit beta IL-12B 
Interleukin-13 IL-13 
Interleukin-15 IL-15RA 
Interleukin-17A IL-17A 
Interleukin-17C IL-17C 
Interleukin-18   IL18 
Interleukin-18 receptor 1 IL-18R1 
Interleukin-20 IL-20 
Interleukin-20 receptor subunit alpha IL-20RA 
Interleukin-22 receptor subunit alpha-1 IL-22 RA1 
Interleukin-24 IL-24 
Interleukin-33 Il-33 
Latency-associated peptide transforming growth factor beta 1 LAP TGF-beta-1 
Leukemia inhibitory factor LIF 
Leukemia inhibitory factor receptor LIF-R 
Macrophage colony-stimulating factor CSF-1 
Macrophage inflammatory protein 1-alpha MIP-1 alpha 
Matrix metalloproteinase-1 MMP-1 
Matrix metalloproteinase-10 MMP-10 
Monocyte chemotactic protein 1 MCP-1 
Monocyte chemotactic protein 2 MCP-2 
Monocyte chemotactic protein 3 MCP-3 
Monocyte chemotactic protein 4 MCP-4 
Natural killer cell receptor 2B4 CD244 
Neurotrophin-3 NT-3 
Neurturin NRTN 
oncostatin-M OSM 
osteoprotegerin OPG 
Programmed cell death 1 ligand 1 PD-L1 
Protein S100-A12 EN-RAGE 
Signalling lymphocytic activation molecule SLAMF1 
SIR2-like protein 2 SIRT2 
STAM-binding protein STMPB 
Stem cell factor SCF 
Sulfotransferase 1A1 ST1A1 
T-cell surface glycoprotein CD5 CD5 
T-cell surface glycoprotein CD6 isoform CD6 
Thymic stromal lymphopoietin TSLP 
TNF-beta TNFB 
TNF-related activation-induced cytokine TRANCE 
TNF-related apoptosis-inducing ligand TRAIL 
Transforming growth factor alpha TGF-alpha 
Tumour necrosis factor ligand superfamily member 12 TWEAK 
Tumour necrosis factor   TNF  
Tumour necrosis factor ligand superfamiliy member 14 TNFSF14 
Tumour necrosis factor receptor superfamily member 9 TNFRSF9 
Urokinase-type plasminogen activator uPA 
Vascular endothelial growth factor A VEGF-A 
 
 
 
 
Supplementary Table 3. Comparison of the mean body mass index (BMI) over time. It showed that 
at week 4 the mean BMI was not significantly different from the mean BMI prior to FMT. At week 12, 
patients had significantly higher BMI relative to pre-FMT, but did not exceed pre-rCDI baseline.  
  Mean BMI Difference (95% CI) P Value 
Week 4 - Pre-FMT 0.0 (-0.3, 0.3) 0.84 
Week 12 - Pre-FMT 0.5 (0.2, 0.8) 0.003 
Week 12 - Week 4 0.4 (0.1, 0.8) 0.006 
 
Response to Reviewers re Submission to Gut Microbes, KGMI-20180038, “Effective fecal 
microbiota transplantation for recurrent Clostridium difficile infection in humans is 
associated with increased signalling in bile acid-farnesoid X receptor-fibroblast growth 
factor pathway” 
Reviewer #2: I would like to thank the authors for revising the manuscript. This is an 
excellent study with potentially important findings regarding the role of Fgf19 and bile acid 
signaling in rCDI recovery. I have only two minor suggestions for improvement: 
Figs 1 and 2: The labeling on the x-axis is somewhat confusing, and providing the BA or 
gene name as a title above the chart may make these figures easier to read. 
Supplementary Table 2 should be S Table 1, since it is referenced first in the text. 
 
Response: Thank you so much for these comments. We agree with your suggestions and have 
revised Figure 1 and Figure 2 to make it easier for readers to understand. We have also 
changed supplementary Table 2 to supplementary Table 1, and changed supplementary Table 
1 to supplementary Table 2 both in the manuscript and in the supplementary material. 
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